| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 2.792 | 19.682 | 40.312 | 23.742 | 30.988 | 40.811 | 87.461 | 169.121 |
| Total Income - EUR | - | - | 2.792 | 19.682 | 40.313 | 23.743 | 30.989 | 40.812 | 87.461 | 169.271 |
| Total Expenses - EUR | - | - | 1.363 | 18.115 | 28.289 | 20.113 | 22.936 | 26.568 | 50.060 | 114.987 |
| Gross Profit/Loss - EUR | - | - | 1.429 | 1.567 | 12.024 | 3.630 | 8.053 | 14.243 | 37.401 | 54.283 |
| Net Profit/Loss - EUR | - | - | 1.346 | 1.313 | 11.621 | 3.392 | 7.749 | 13.897 | 36.544 | 50.252 |
| Employees | - | - | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 10 |
Check the financial reports for the company - Alvada 2012 Fda Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 205 | 1.850 | 1.417 | 1.048 | 722 | 499 | 298 | 32.091 |
| Current Assets | - | - | 2.180 | 5.661 | 23.027 | 29.048 | 28.439 | 41.407 | 55.672 | 76.973 |
| Inventories | - | - | 61 | 0 | 0 | 0 | 0 | 0 | 346 | 0 |
| Receivables | - | - | 980 | 2.335 | 7.473 | 3.621 | 5.505 | 5.220 | 50.097 | 34.814 |
| Cash | - | - | 1.138 | 3.326 | 15.554 | 25.427 | 22.933 | 36.187 | 5.228 | 42.159 |
| Shareholders Funds | - | - | 1.389 | 2.676 | 11.671 | 14.842 | 18.007 | 31.959 | 36.593 | 54.797 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 995 | 4.834 | 12.773 | 15.254 | 11.154 | 9.947 | 19.378 | 54.267 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8121 - 8121" | |||||||||
| CAEN Financial Year |
8121
|
|||||||||
Comments - Alvada 2012 Fda Srl